Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status.

培美曲塞 医学 卡铂 打开标签 肿瘤科 化疗 内科学 肺癌 临床研究阶段 顺铂 随机对照试验
作者
Ki Hyeong Lee,Eun Kyung Cho,Jin Seok Ahn,Dong‐Wan Kim,Byoung Chul Cho,Ki Hyeong Lee,Sang‐We Kim
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (15_suppl): 9081-9081 被引量:1
标识
DOI:10.1200/jco.2016.34.15_suppl.9081
摘要

9081 Background: We aimed to compare pemetrexed/carboplatin doublet (PC) versus pemetrexed singlet (P) in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non–small-cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Methods: In an open-label multicenter phase III randomized trial, elderly patients aged 70 or more with advanced non-squamous NSCLC, ECOG PS of 0-1, no prior chemotherapy, adequate organ function and measurable disease were assigned to PC doublet (P, 500 mg/m2; C, area under the curve of 5) or P singlet (500 mg/m2) after stratified randomization according to center, gender and Charson Comorbidity Index (CCI). The treatment was given every 3 weeks till disease progression, unacceptable toxicity or withdrawal of consent. However, carboplatin was given only for the first four cycles. The primary end point was progression-free survival (PFS). Secondary endpoints included overall survival, response rate, and safety. Results: A total of 267 eligible patients were enrolled from six centers between March 2012 and October 2015; median age was 74 years (70~86); 95% had PS of 1; 65% were men; and 63% had CCI of 1 or more. The median PFS was 5.5 months for PC doublet and 4.3 months for P singlet, respectively (hazard ratio [HR], 0.85; 95% CI, 0.64 to 1.12; P = 0.246). The median survival time was 12.5 months for PC and 9.3 months for P, respectively (HR, 1.03; 95% CI, 0.70 to 1.52; P = 0.865). There were 13 deaths (4.9%) during the treatment. Conclusions: The addition of carboplatin to pemetrexed did not show the improvement of survival time in elderly patients aged 70 or more with advanced non-squamous NSCLC and ECOG PS of 0-1. Updated data will be presented. Clinical trial information: NCT01593293.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小点点cy_完成签到,获得积分10
刚刚
刚刚
wrrr完成签到,获得积分10
刚刚
充电宝的应助被dadsafyf采纳,获得10
刚刚
whj完成签到 ,获得积分10
刚刚
刚刚
刚刚
宿宿完成签到,获得积分10
1秒前
1秒前
KKH完成签到 ,获得积分10
1秒前
2秒前
2秒前
wwwww完成签到,获得积分20
2秒前
俊逸的问兰完成签到,获得积分10
2秒前
xiaochen发布了新的文献求助10
2秒前
Haier完成签到,获得积分10
2秒前
2秒前
玉面豪杰完成签到 ,获得积分10
2秒前
文俊辉唯一的wife完成签到,获得积分10
2秒前
小Q完成签到,获得积分10
2秒前
慈祥的书本完成签到,获得积分10
3秒前
3秒前
Lily1983完成签到,获得积分10
3秒前
神勇化蛹发布了新的文献求助10
3秒前
英姑的应助被周俊丞采纳,获得10
3秒前
科研通AI2S的应助被霁月采纳,获得10
3秒前
QDU的应助被simon采纳,获得10
4秒前
wanci的应助被沉静的立轩采纳,获得30
4秒前
CipherSage的应助被Len采纳,获得10
4秒前
sjdhasj完成签到,获得积分20
4秒前
xihan完成签到,获得积分10
4秒前
Hua发布了新的文献求助10
4秒前
4秒前
甜甜的觅夏完成签到,获得积分10
4秒前
晨曦完成签到,获得积分10
4秒前
qyc完成签到,获得积分10
5秒前
aaaaa完成签到,获得积分10
5秒前
ZR发布了新的文献求助30
5秒前
三岁啊吉吉完成签到,获得积分10
5秒前
开朗寇完成签到,获得积分10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162